Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists.
about
Adenosine receptors as therapeutic targetsTranslocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathwaysRemote control of neuronal signaling.Probing the binding site of the A1 adenosine receptor reengineered for orthogonal recognition by tailored nucleosides.Click modification in the N6 region of A3 adenosine receptor-selective carbocyclic nucleosides for dendrimeric tethering that preserves pharmacophore recognition.Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.Probing GPCR structure: adenosine and P2Y nucleotide receptors.Action of nucleosides and nucleotides at 7 transmembrane-spanning receptors.Neoceptors: reengineering GPCRs to recognize tailored ligandsThe A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.A compendium of cyclic sugar amino acids and their carbocyclic and heterocyclic nitrogen analogues.Synthesis of N6-substituted 3'-ureidoadenosine derivatives as highly potent agonists at the mutant A3 adenosine receptor.Structural Probing and Molecular Modeling of the A₃ Adenosine Receptor: A Focus on Agonist Binding.Antiproliferative and protein kinase binding activities of Some N6, 5'-bis-ureido 5'-amino-5'-deoxyadenosine derivatives.Synthesis of 3'-amino-3'-deoxyguanosine and 3'-amino-3'-deoxyxyloguanosine monophosphate HepDirect prodrugs from guanosine.Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design.
P2860
Q24632095-7CA90B8F-4996-464A-A2F9-20BC9C54EEC4Q24646643-528900CC-CBC8-43B0-B27F-8AEC3B8CDE17Q34858531-D97C32FB-7B09-4D8D-B9AF-DFCBB91A5AE0Q35119322-EB9D6E88-E85D-4F31-9197-01AF947BF9B5Q35795478-FA001617-B3C9-4AF6-A6B7-9D4F6BA46B11Q36146803-74D90FFE-662B-4B5A-8EEC-83E66EBF99F5Q36630298-A7FA2DDF-1A11-45C0-AFA3-D2D0901A4A46Q36635966-9C68A14E-FCD9-4402-9A0F-1A5E762638CAQ36728991-E05641EA-D024-4CDA-8307-E097FC770079Q37957791-C3E600B1-7857-4DE3-980D-D2DF3A92D83BQ38129764-30F6D0A2-2196-4F17-A867-24BF7EF84745Q38503164-D918EBAD-30D2-4728-BBAD-8986DC4D3689Q38911603-85FB18AB-DE1A-45ED-AD3C-87590B97EAC8Q39735284-E819B3EE-3F1A-4E16-BA29-284FDD87A8D6Q43150268-F7D330CD-0EF3-4068-8E17-BA17F2DDB33CQ47348749-5F56884E-8DE3-464D-AED6-D2F621369B85
P2860
Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Orthogonal activation of the r ...... tailored nucleoside agonists.
@ast
Orthogonal activation of the r ...... tailored nucleoside agonists.
@en
type
label
Orthogonal activation of the r ...... tailored nucleoside agonists.
@ast
Orthogonal activation of the r ...... tailored nucleoside agonists.
@en
prefLabel
Orthogonal activation of the r ...... tailored nucleoside agonists.
@ast
Orthogonal activation of the r ...... tailored nucleoside agonists.
@en
P2093
P2860
P50
P356
P1476
Orthogonal activation of the r ...... tailored nucleoside agonists.
@en
P2093
Ae Yil Kim
Bruce T Liang
Hea Ok Kim
Heng T Duong
Lak Shin Jeong
Liaman Mamedova
Myong Jung Kim
Philippe Van Rompaey
Soo-Kyung Kim
Tatiana Sonina
P2860
P304
P356
10.1021/JM050968B
P407
P577
2006-05-01T00:00:00Z